KLP Kapitalforvaltning AS Buys 1,600 Shares of Vaxcyte, Inc. $PCVX

KLP Kapitalforvaltning AS grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 7.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 24,600 shares of the company’s stock after acquiring an additional 1,600 shares during the period. KLP Kapitalforvaltning AS’s holdings in Vaxcyte were worth $800,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. AlphaQuest LLC bought a new position in shares of Vaxcyte during the 1st quarter valued at approximately $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Vaxcyte during the 1st quarter valued at approximately $35,000. IFP Advisors Inc grew its position in shares of Vaxcyte by 376.4% during the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock valued at $62,000 after acquiring an additional 1,306 shares during the period. Advisors Asset Management Inc. grew its position in shares of Vaxcyte by 81.6% during the 1st quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock valued at $73,000 after acquiring an additional 867 shares during the period. Finally, Twin Tree Management LP grew its position in shares of Vaxcyte by 301.3% during the 1st quarter. Twin Tree Management LP now owns 2,365 shares of the company’s stock valued at $89,000 after acquiring an additional 3,540 shares during the period. 96.78% of the stock is owned by institutional investors.

Vaxcyte Stock Performance

Vaxcyte stock opened at $43.59 on Friday. The firm’s fifty day moving average price is $34.35 and its 200-day moving average price is $33.65. The stock has a market cap of $5.66 billion, a P/E ratio of -10.61 and a beta of 1.12. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $118.54.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the prior year, the company earned ($1.10) EPS. On average, analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on PCVX shares. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 target price for the company. Cowen restated a “buy” rating on shares of Vaxcyte in a research note on Thursday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Vaxcyte presently has a consensus rating of “Moderate Buy” and an average target price of $106.25.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.